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Abstract: Multiple myeloma (MM) has one of the highest risks of venous thromboembolism
(VTE) of all cancers due to pathologic changes and treatment-related exposures. This study
assessed the one-year incidence of VTE in newly diagnosed MM and to determine the baseline and
time-varying treatment-related factors associated with VTE risk in a U.S.-based cohort. MM patients
were identified and age, gender, and baseline comorbidities were determined. Treatment-related
exposures included thalidomide derivatives (IMIDs), proteasome inhibitors, cytotoxic chemotherapy,
steroids, erythropoietin-stimulating agents (ESAs), stem cell transplants (SCT), hospitalizations,
infection, and central venous catheters (CVC). Multiple statistical models were used including a
baseline competing risks model, a time-varying exposure Cox proportional hazard (CPH) model,
and a case-time-control analysis. The overall incidence of VTE was 107.2 per 1000 person-years
with one-half of the VTEs occurring in the first 90 days. The baseline model showed that increasing
age, heart failure, and hypertension were associated with one-year incidence of VTE. MM-specific
IMID treatment had lower than expected associations with VTE based on prior literature. Instead,
exposure to ESAs, SCT, CVC, and infection had higher associations. Based on these results, VTE
risk in MM may be less straightforward than considering only chemotherapy exposures, and other
treatment-related exposures should be considered to determine patient risk.
Keywords: multiple myeloma; venous thromboembolism; deep vein thrombosis; competing risks;
case-time-control study design
1. Introduction
Multiple myeloma (MM) has one of the highest risks of thrombosis among all cancers due
to disease-related pathological changes and treatment [1–3]. Malignancy induces a prothrombotic
state, which includes activation of the coagulation cascade, increase in pro-inflammatory cytokines,
and inhibition of natural anticoagulants [3–5]. This is further exacerbated by cancer treatment and
surgery. Thalidomide and lenalidomide (IMIDs) are well known to be associated with increased
risk of thrombosis [6], especially when combined with high-dose steroids and other chemotherapy,
with incidence approaching 25% in some studies [7–10]. Other common MM treatments include
proteasome inhibitors (PIs; bortezomib, carfilzomib) and cytotoxic therapies (cyclophosphamide,
melphalan, others), which have been shown to have a lower, though still increased, risk of venous
thromboembolism (VTE) compared to IMIDs [11]. Other disease-related factors with potential to
increase thrombotic risk include use of central venous catheters (CVC), erythropoietin-stimulating
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agents (ESAs), hospitalization, and infection [5,12–18]. Due to this inherent increased risk of thrombosis
with MM, guidelines recommend routine thromboprophylaxis with anticoagulants (low-molecular
weight heparins (LMWH), warfarin, etc.) or aspirin especially among those receiving IMIDs with
steroids [19,20].
Previous studies have assessed VTE risk in MM during randomized-controlled trials (RCTs)
or in small observational studies with limited information about other risk factors associated with
MM-related thrombosis [8–10,21]. These studies have also considered static treatment, not taking into
account the time-varying nature of chemotherapy regimens and other disease-related exposures that
may have an acute impact on thrombosis risk, e.g., supportive therapies [12,14–18]. As these exposures
are potentially modifiable or detectable, identifying high-risk exposures may lead to better prediction
of thrombotic events and lead to enhanced surveillance or prevention efforts.
The objective of this study was to determine the one-year incidence of VTE in newly diagnosed
MM, assess the association of baseline characteristics and thrombosis, and to investigate the acute
association between disease-related treatments and exposures with thrombosis. While previous studies
have shown increased risks associated with specific treatments, our a priori hypothesis was that other
treatment exposures occurring during treatment, such as supportive therapy or hospitalizations, may
be attributing the observed increased risk of thrombosis associated with MM.
2. Methods
2.1. Data Source and Study Sample
This was a retrospective cohort study utilizing an extract of patients with at least two diagnoses of
MM (International Classification of Diseases codes, 9th Revision (ICD-9): 203.0x) at least 14 days
apart during 2008–2013 from the Truven MarketScan Commercial Claims and Encounters and
Medicare Supplemental databases. The MarketScan data are administrative claims data including
medical diagnostic and procedural billing information and pharmacy fill records for those with
commercial insurance linked to demographic and insurance enrollment information for each individual.
The dataset represents patients from all 50 U.S. states and is representative based on demographic
and geographic characteristics. The data do not include detailed clinical information (e.g., laboratory
values or cancer stating) but are a complete record of a patient’s healthcare utilization.
For further inclusion, subjects were required to have a minimum of six months of continuous
medical and pharmacy insurance coverage prior to the first MM diagnosis and be at least 18 years or
older at diagnosis. Subjects also could not have a previous diagnosis of another cancer or a thrombotic
outcome event during the six-month, pre-index period. Use of the MarketScan data was approved by
the University of Kentucky Institutional Review Board (15-0334-P6A).
2.2. Subject Characteristics
Age was assessed on the MM index date and gender was linked from the enrollment file.
The Charlson Comorbidity Index was used to assess comorbidity burden based on the ICD-9 coding
algorithm by Quan et al. [22] and the total score was further categorized by 0, 1–2, 3–4, and 5+ groups
with individual comorbidities also reported. Anemia in the pre-index period was also assessed using
ICD-9 codes.
2.3. Outcome Events
Deep vein thrombosis (DVT) and pulmonary embolism (PE) VTE events were assessed based on
previously published ICD-9 algorithms [23–25]. Date of death was based on discharge status codes on
hospital or hospice records. Loss to follow-up occurred when continuous insurance coverage ended
during the follow-up period or follow-up terminated at the end of the data (December 2013). All other
individuals were censored after one year of follow-up. If a thrombosis occurred on the same day as
death, the event was recorded as the thrombosis as it was the main outcome of interest in this study.
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Subjects were followed in this retrospective cohort until one of the following occurred: (1) a thrombosis
event; (2) death; (3) loss to follow-up; or (4) end of the one-year study period.
2.4. Statistical Analysis
Person time was calculated correcting for the differential follow-up of each subject. The incidence
rate of VTE was reported as the rate per 1000 person-years. Incidence rates were calculated at several
intervals (30, 60, 90, 180 days) as well as for the complete one-year study period.
Due to the high risk of death associated with MM as well as the baseline risk of death in the older
population, it was necessary to assess thrombosis alongside the competing risk of death over longer
follow-up periods [26]. In a survival analytic framework, death prevents the occurrence of an outcome
of interest; thus, death cannot simply be considered a censored observation [27]. However, there is no
statistical framework to assess competing risks with time-varying covariates. Utilization of a traditional
Cox proportional hazard (CPH) model in this example, which allows for time-varying exposures,
would have produced bias estimates of the association especially as the cumulative incidence of
death increases over the one-year period [26]. Thus, three statistical modeling approaches were
used to investigate the influence of baseline, time-independent factors as well as time-dependent,
treatment-related exposures separately.
2.4.1. Model #1—Competing Risks Survival Analysis
The association of VTE with baseline demographic and clinical characteristics at diagnosis was
assessed using a competing risks regression model using the complete follow-up time for each
individual up to one year of follow-up. Post-diagnosis, treatment-related covariates were excluded
from this model to avoid the bias of ignoring competing risks. In this model, the dependent outcome
has three levels: 0 = censored; 1 = thrombosis; and 2 = death. Subdistribution hazard ratios (HR) and
their 95% confidence intervals (CI) for the association between each baseline covariate and thrombotic
events were estimated for each baseline covariate included in the model. A post-hoc analysis restricted
the model to the first 90 days after diagnosis to explore the association in the early post-diagnosis phase,
which showed no significant differences from the main model. The one-year cumulative incidence of
thrombotic events was reported for the total cohort.
2.4.2. Model #2—Case-Time-Control Analysis
The case-time-control study design incorporates both the case-control and case-crossover study
designs. Since it assigns cases by outcome events, it is not sensitive to the bias associated with
competing risks. The case-time-control study design assumes that if an exposure causes a transient
increase in the risk of an event then it will be more common in the “hazard” period immediately before
an event; defined for this study as the 30 days immediately proximal to the event. A washout period
was used between days 31–60 and the comparison period consisted of days 61–90 before the event [28].
Cases included 502 VTEs, with at least a 90-day pre-event exposure window to allow for the hazard,
washout, and comparison periods. Each case was matched with up to four controls based on the exact
year of MM diagnosis and who had overlapping enrollment periods using incidence density sampling
with replacement. Matching gave 2008 matched pairs with 1732 unique controls. Exposures in the
hazard and comparison periods are compared for each matched pair and adjusted odds ratios (OR)
are reported. Control subjects serve to control for the exposure trends over time rather than individual
characteristics [28]. All demographic and time-independent characteristics, as well as unobserved
confounders, are self-controlled and not included in the regression [28,29].
Exposures were assessed as binary indicators in each exposure period and included: IMIDs
(thalidomide, lenalidomide, pomalidomide); PIs (bortezomib, carfilzomib); steroids (dexamethasone,
prednisone, prednisolone); cytotoxic chemotherapy (doxorubicin, cyclophosphamide, melphalan,
vincristine, etoposide, cisplatin); stem cell transplant (SCT); hospitalization (other than SCT-related
hospitalizations); colony stimulating factors (CSF); central venous catheter (CVC); ESAs; and infection.
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Infection was broadly coded to encompass all bacterial, viral, and fungal infections. Because
anticoagulation was highly collinear with IMID treatment, it was not assessed in any of the models.
Conditional logistic regression was used to estimate the adjusted case-time-control OR and 95% CIs
were calculated by bootstrapping the sample with 5000 replications [28].
Sensitivity analyses were conducted varying the hazard, washout, and comparison exposure
windows, which showed that the results were not sensitive to the specification. Further, for both
Model #2 and Model #3 below, MM-specific treatments were categorized based on typical regimens
(e.g., IMID + PI, IMID + steroid, PI + steroid, etc.) as well as separating the IMID group into
individual products (thalidomide, lenalidomide, pomalidomide). The findings were not sensitive to
these specifications.
2.4.3. Model #3—Time-Varying Cox Proportional Hazard Models
Our previous work showed a high rate of thromboembolism associated with MM in the first
90 days after diagnosis [26]. Higher risk in the early stages of diagnosis and treatment may be
related to high tumor burden and release of thrombogenic factors with initiation of treatment [7,30,31].
During this initial follow-up, mortality is lower; thus, the bias introduced by ignoring competing risks
will be lower. Thus, a Cox proportional hazard (CPH) regression was also modeled to investigate
the association between baseline factors as well as time-varying treatments and treatment-related
exposures following patients for only the first 90 days after diagnosis.
All exposures from the case-time-control analysis were modeled as time-varying exposures by
daily intervals. A residual risk period was programmed for each exposure to account for the prolonged
increase in risk of thromboembolism event after an exposure occurs. Two models were estimated using
7 and 14 days for this risk window, which was added to the total exposure window. For outpatient
prescription products, this included the dispensing date, days supplied, and the 7- or 14-day period.
Inpatient chemotherapies and diagnoses included the day of exposure plus the additional risk window.
Hospitalizations (SCT and non-SCT) included the day of admission, length of stay, and the risk window.
Sensitivity analyses for the CPH model included stratifying by exposure to prophylactic
anticoagulation and whether or not MM treatment was initiated within this initial 90-day period.
All baseline characteristics were included in the model and the proportionality assumption was tested
for each. HRs and 95% confidence intervals were reported for all time-varying exposures. All analyses
were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).
3. Results
3.1. Incidence of Thrombosis
There were 1050 thrombosis events observed in 13,700 individuals during the one-year follow-up.
This included 756 DVTs (72% of events) and 294 PEs (28%). Nearly one-half (N = 520, 49.5% of events)
occurred within the first 90 days after MM diagnosis. The cohort contributed 9791.4 person-years
of follow-up time for a one-year incidence rate of thrombosis of 107.2 (95% CI, 100.0–113.9) events
per 1000 person-years. The highest incidence of thrombosis was in the first 30 days with 251 events
and an incidence rate of 234.2 (95% CI, 206.5–264.5) per 1000 person-years. The rate of thrombotic
events decreased over the 60-, 90-, and 180-day intervals: 196.6 (95% CI, 178.3–216.4), 171.7 (95% CI,
157.4–187.0), 140.1 (95% CI, 130.5–150.1), per 1000 person-years, respectively. There were 384 deaths
experienced as a competing risk and a total of 479 deaths during the study period with an incidence
rate of 48.9 (95% CI, 44.7–53.5) deaths per 1000 person-years.
The one-year cumulative incidence of thrombosis was 9.2% (95% CI, 8.7%–9.7%) for the total
cohort (Figure 1). The cumulative incidence in the 18–34 age group was 5.6% (95% CI, 3.3%–9.6%) and
8.6% (95% CI, 7.9%–9.4%) in the 35–64 age group. There were no differences between the cumulative
incidence of the 65–74 age group (10.2% (95% CI, 9.1%–11.5%)) and the 75 and older age group
(9.9% (95% CI, 8.9%–11.1%)).
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showed a protective effect with HR = 0.7 (95% CI, 0.7–0.8) compared to males. Increasing comorbidity 
burden had no impact on the hazard of thrombosis at baseline; however, some individual 
comorbidities at baseline did increase the risk. Those with congestive heart failure (CHF) had 70% 
higher hazard (HR = 1.7 (95% CI, 1.4–2.1)) and those with hypertension had 20% higher hazard (HR 
= 1.2 (95% CI, 1.0–1.3)). There were no other significant associations observed for the other included 
covariates. In the 90-day post-hoc analysis, the associations observed were nearly identical and 
included no additional significant associations compared to the primary, one-year model (results not 
shown). 
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Figure 1. Cumulative incidence and 95% confidence interval of venous thromboembolism (VTE) from
diagnosis of multiple myeloma.
3.2. Competing Risk Model Results
Cohort baseline characteristics are summarized in Table 1. Among these characteristic in
the baseline competing risk model, older age was associated with an increase in the hazard of
thrombosis for the 35–64 and 65–74 age groups compared to the 18–34 reference group (Table 2).
Female gender showed a protective effect with HR = 0.7 (95% CI, 0.7–0.8) compared to males. Increasing
comorbidity burden had no impact on the hazard of thrombosis at baseline; however, some individual
comorbidities at baseline did increase the risk. Those with congestive heart failure (CHF) had 70%
higher hazard (HR = 1.7 (95% CI, 1.4–2.1)) and those with hypertension had 20% higher hazard
(HR = 1.2 (95% CI, 1.0–1.3)). There were no other significant associations observed for the other
included covariates. In the 90-day post-hoc analysis, the associations observed were nearly identical
and included no additional significant associations compared to the primary, one-year model (results
not shown).
Table 1. Baseline characteristics of the cohort, cases, and controls at diagnosis of multiple myeloma.
Overall Cohort N = 13,700
N %
Age Mean63.9
SD
13.7
18–34 283 2.1
35–64 7389 53.9
65–74 2648 19.3
75+ 3380 24.7
Gender
Male 6625 48.4
Female 7075 1.6
Charlson Comorbidity Index Mean1.1
SD
1.5
0 6892 50.3
1–2 4758 34.7
3–4 1476 10.8
5+ 574 4.2
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Table 1. Cont.
Overall Cohort N = 13,700
N %
Comorbidity
MI 251 1.8
CHF 933 6.8
PVD 841 6.1
Dementia 123 0.9
COPD 1817 13.3
Rheumatism 734 5.4
PUD 134 1.0
Mild liver disease 551 4.0
Diabetes 2814 20.5
Diabetes w/complications 755 5.5
Paralysis 68 0.5
Renal disease 1826 13.3
Severe liver disease 45 0.3
CVD 910 6.6
HIV/AIDS 30 0.2
Hypertension 6466 47.2
CHD 1725 12.6
Lipids 4260 31.1
Anemia 3727 27.2
MI = myocardial infarction; CHF = congestive heart failure; PVD = peripheral vascular diseases; COPD = chronic
obstructive pulmonary disease; PUD = peptic ulcer disease; CVD = cerebrovascular disease; CHD = coronary
heart disease.
Table 2. Results of baseline competing risk survival analysis predicting venous thromboembolism
outcome controlling for baseline factors.
Covariate sHR 95% Confidence Interval
Age
18–34 Ref. Ref. Ref.
35–64 * 1.7 1.0 3.0
65–74 * 1.9 1.1 3.2
75+ 1.6 0.9 2.7
Gender
Male Ref. Ref. Ref.
Female * 0.7 0.7 0.8
Charlson Comorbidity Index
0 Ref. Ref. Ref.
1–2 1.0 0.5 2.1
3–4 0.8 0.5 1.3
5+ 1.0 0.8 1.2
Comorbidities
MI 0.9 0.6 1.4
CHF * 1.7 1.4 2.1
PVD 1.2 0.9 1.5
Dementia 1.2 0.7 2.1
COPD 0.9 0.8 1.1
Rheumatism 0.9 0.6 1.2
PUD 0.8 0.5 1.5
Mild liver disease 0.8 0.5 1.1
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Table 2. Cont.
Covariate sHR 95% Confidence Interval
Comorbidities
Diabetes 1.0 0.8 1.2
Diabetes with complications 1.1 0.8 1.5
Paralysis 1.4 0.8 2.5
Renal disease 1.0 0.8 1.3
Severe liver disease 1.1 0.4 3.0
CVD 1.0 0.8 1.3
Hypertension * 1.2 1.0 1.3
CHD 1.0 0.8 1.1
Lipids 1.0 0.9 1.1
Anemia 0.9 0.8 1.1
sHR = subdistribution hazard ratio; CI = confidence interval; MI = myocardial infarction; CHF = congestive heart
failure; PUD = peptic ulcer disease; CVD = cerebrovascular disease; CHD = coronary heart disease; Ref. = Reference
category; * p < 0.05.
3.3. Case-Time-Control Model
Table 3 shows the exposure profiles of cases and controls as well as the adjusted case-time-control
OR for the odds of thrombosis with each exposure. IMID use was higher in the hazard period and had
an adjusted OR of 1.61 (95% CI, 1.11–2.33), showing increased transient risk of IMIDs and thrombotic
events. PI use was associated with lower odds (aOR = 0.65, (95% CI, 0.35–1.22)). The highest transient
risk of thrombosis was shown for SCT (OR = 3.76, (95% CI, 3.07–4.61)), CVC (OR = 2.56, (95% CI,
2.28–2.87)), ESAs (OR = 3.82, (95% CI, 2.55–5.70)), and infection (OR = 2.51, (95% CI, 1.95–3.24)).
All-cause hospitalization also had increased odds of thrombosis (OR = 1.24, (95% CI, 1.15–1.35)).
3.4. 90-Day Time-Varying Exposure Model
After adjustment for treatment exposures, there were no significant baseline characteristics associated
with thromboembolism in the first 90 days after diagnosis. Among MM-specific chemotherapy, thalidomide
(HR = 1.4, (95% CI, 1.1–1.8)) and steroids (HR = 1.5, (95% CI, 1.2–2.0)) had an increased hazard of
thromboembolism in the first 90 days after diagnosis (Table 4). Stronger contributions were observed
for infections (HR = 2.3, (95% CI, 1.8–3.0)), CVC use (HR = 2.0, (95% CI, 1.6–2.5)), and all-cause
hospitalizations (HR = 8.9, (95% CI 7.3–11.0)). The directionality and magnitude of these findings were
not sensitive to models including seven-day exposure windows or when stratified by those receiving
anticoagulation or MM treatment in the 90-day period.
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Table 3. Results of case-time-control analysis predicting the time-varying association of treatment exposures and thrombosis.
Treatment/Exposure Cases Exposure Controls Exposure CTC Adjusted Odds Ratio
Hazard N (%) Comparison N (%) Hazard N (%) Comparison N (%) Point Estimate 95% CI
Thalidomide and derivatives 119 (23.7) 107 (21.3) 147 (8.5) 153 (8.8) 1.61 1.11 2.33
Proteasome inhibitors 108 (21.5) 121 (24.1) 140 (8.1) 180 (10.4) 0.65 0.35 1.22
Steroids 126 (25.1) 135 (26.9) 178 (10.3) 198 (11.4) 1.58 0.95 2.65
Cytotoxic chemotherapy 46 (9.2) 56 (11.2) 99 (5.7) 82 (4.7) 0.44 0.31 0.63
Stem cell transplant 28 (5.6) 11 (2.2) 15 (0.9) 18 (1.0) 3.76 3.07 4.61
Hospitalization 65 (13.0) 58 (11.6) 70 (4.0) 75 (4.3) 1.24 1.15 1.35
Colony stimulating factors 20 (4.0) 22 (4.4) 44 (2.5) 34 (2.0) 0.48 0.33 0.70
Central venous catheters 57 (11.4) 23 (4.6) 42 (2.4) 38 (2.2) 2.56 2.28 2.87
Erythropoietin-stimulating agents 44 (8.8) 27 (5.4) 47 (2.7) 47 (2.7) 3.82 2.55 5.70
Infection 74 (14.7) 45 (9.0) 90 (5.2) 87 (5.0) 2.51 1.95 3.24
CTC = case-time-control; CI = confidence interval.
Table 4. Cox proportional hazard model for VTE in the first 90 days after multiple myeloma diagnosis with time-varying exposures.
Time-Varying Exposures HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Overall Treated Treated + Anticoagulation Treated – Anticoagulation Untreated
Thalidomide derivatives 1.38 1.06 1.79 1.29 0.97 1.72 1.07 0.62 1.85 1.58 1.13 2.22 – – –
Proteasome Inhibitors 0.80 0.51 1.26 0.73 0.46 1.16 1.93 0.74 5.06 0.52 0.31 0.89 – – –
Steroids 1.54 1.21 1.96 2.18 1.60 2.95 2.81 1.43 5.55 2.05 1.45 2.90 – – –
Cytotoxic chemotherapy 1.15 0.76 1.73 1.37 0.89 2.10 0.80 0.31 2.07 1.61 0.99 2.61 – – –
Infections 2.29 1.80 2.92 1.88 1.28 2.77 1.42 0.49 4.13 1.84 1.21 2.79 2.15 1.55 2.98
Erythropoiesis-stimulating agents 1.03 0.64 1.67 1.08 0.63 1.87 1.09 0.37 3.20 1.33 0.71 2.49 * * *
Colony stimulating factors 0.93 0.43 1.99 1.09 0.50 2.39 2.28 0.47 10.94 0.93 0.37 2.33 * * *
Stem cell transplant 2.40 0.99 5.83 2.74 1.11 6.72 * * * 3.74 1.51 9.27 – – –
Central venous catheters 2.02 1.65 2.49 1.51 1.14 2.01 1.42 0.79 2.57 1.60 1.16 2.22 3.00 2.24 4.11
Hospitalization 8.90 7.26 10.92 7.16 5.40 9.50 1.50 0.78 2.90 12.02 8.57 16.84 15.72 11.52 21.44
HR = hazard ratio; CI = confidence interval; * Stable estimated could not be obtained due to low sample size. Note: All other covariates form Table 2 were included but were not
significant predictors.
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4. Discussion
Treatment advances over the last decade for MM have led to an increase in median survival
greater than five years [32,33]. However, thrombotic complications have emerged as serious adverse
effects of treatment; prompting recommendations for thromboprophylaxis in guidelines in this patient
population [34,35]. Despite the known risk, the pathogenesis of thrombosis in MM is poorly understood
due to the various factors that can impart risk including patient characteristics, disease-related factors,
as well as treatment-related risks [3]. Although thrombotic events have been shown to have a negligible
impact on overall survival in MM [33], thrombosis events can cause interruption in therapy as well
as tremendous economic and humanistic burdens in the MM population [36,37]. Recent American
Society of Clinical Oncology guidelines have called for better evidence regarding the increased risk of
thrombosis and MM so that prevention efforts can be focused on periods of highest risk [38].
This study investigated both baseline and time-varying factors related to thrombosis risk in
newly diagnosed MM. There were few baseline factors found to be associated with risk in our study,
suggesting that risk may be associated with factors related to treatment of MM instead of pre-existing,
patient-related factors. Further, these baseline characteristics were not significant after treatment was
included in a time-varying CPH model. We observed that nearly one-half of all thrombotic events
occurred within the first 90 days after MM diagnosis. This underscores the need to identify early risk
factors at diagnosis to guide the utilization of thromboprophylaxis—especially in the first 90 days
of treatment.
Treatment-related risks have been investigated in RCTs and small prospective studies using static
treatment group assignment, and have not necessarily considered other disease-related exposures
that may contribute to risk [3,10,11]. We considered several disease- and treatment-related factors
including chemotherapy, supportive treatments, hospitalizations, and infections, which have all
been shown to have increased risk of thrombosis in patients with cancer but have never been
concurrently investigated [3]. Our findings suggest lower risks associated with chemotherapy
regimens including IMIDs, PIs, steroids, and cytotoxic therapies than what may be expected based
on prior literature [6,11]. Instead, the highest exposure associations were found for infections,
CVC and hospitalizations. This suggests that simple association between treatment groups is not
straightforward when considering risk and that other exposures, which may be downstream from the
active chemotherapy treatment such as supportive therapies, may contribute more risk than previously
acknowledged. This is strengthened by multiple methodologies showing similar results in this study.
Our study is subject to several limitations inherent to claims-based studies [39,40]. We relied on
ICD-9 coding available in the claims to diagnose study subjects with outcome events and comorbidities.
It is impossible to confirm a positive diagnosis using these data; however, claims-based coding
algorithms for VTE have been shown to perform strongly especially when there is a high risk
of VTE in the population [24,41]. Further, information regarding MM severity and staging is not
available in claims data and, thus, could not be included here. This study is strengthened by use of
statistical analyses to avoid potential shortfalls. We used a competing risks framework given that the
outcome events cannot be considered independent of each other, i.e., experiencing one may preclude
experiencing another or one event may cause another. Failure to do so can overestimate survival for
traditional Kaplan-Meier or CPH analyses and lead to inflated cumulative incidence functions and
biased associations [27]. In this study, this would have overestimated the cumulative incidence to be
nearly 11% over the one-year study period and could bias any variables more strongly associated with
death [26]. For this population, the competing risk of death is a contribution by many factors including
the advanced age of the cohort, having cancer, as well as the risk of death from the other outcome
events [27].
5. Conclusions
This study found an incidence rate of thrombotic events of 107.2 events per 1000 person-years in a
U.S. cohort with multiple myeloma. Nearly one-half of all events occurred in the 90 days after multiple
Healthcare 2016, 4, 93 10 of 12
myeloma diagnosis. Other than IMIDs only, additional MM treatment-related risk factors for VTE
included stem cell transplants, central venous catheters, ESAs, infection, and all-cause hospitalization.
Consideration of high-risk exposures may guide clinicians to periods where increased surveillance or
prophylactic interventions may be most impactful.
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